Long non-coding RNA FOXD3 antisense RNA 1 augments anti-estrogen resistance in breast cancer cells through the microRNA-363/ trefoil factor 1/ phosphatidylinositol 3-kinase/protein kinase B axis

References

• Perez-Garcia J, Munoz-Couselo E, Soberino J, et al. Targeting FGFR pathway in breast cancer. Breast. 2018;37:126–133.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Cronin KA, Lake AJ, Scott S, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer. 2018;124(13):2785–2800.
   PubMed Web of Science ®Google Scholar
• Lambert LK, Balneaves LG, Howard AF, et al. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors. BMC Cancer. 2018;18(1):732.
   PubMed Web of Science ®Google Scholar
• Ramchand SK, Cheung YM, Yeo B, et al. The effects of adjuvant endocrine therapy on bone health in women with breast cancer. J Endocrinol. 2019;241(3):R111–R24.
   PubMed Web of Science ®Google Scholar
• Lu PW, Li L, Wang F, et al. Retracted: inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway. J Cell Physiol. 2019;234(2):1904–1912.
   PubMed Web of Science ®Google Scholar
• Mf M, Collado-Gonzalez Mdel M, Mp F-P, et al. Promoting E2F1-mediated apoptosis in oestrogen receptor-alpha-negative breast cancer cells. BMC Cancer. 2014;14(1):539.
   PubMedGoogle Scholar
• Semreen MH, Alniss H, Cacciatore S, et al. GC-MS based comparative metabolomic analysis of MCF-7 and MDA-MB-231 cancer cells treated with Tamoxifen and/or Paclitaxel. J Proteomics. 2020;225:103875.
   PubMed Web of Science ®Google Scholar
• Jia X, Hong Q, Lei L, et al. Basal and therapy-driven hypoxia-inducible factor-1alpha confers resistance to endocrine therapy in estrogen receptor-positive breast cancer. Oncotarget. 2015;6(11):8648–8662.
   PubMedGoogle Scholar
• Hou TY, Nandu T, Li R, et al. Characterization of basal and estrogen-regulated antisense transcription in breast cancer cells: role in regulating sense transcription. Mol Cell Endocrinol. 2020;506:110746.
   PubMed Web of Science ®Google Scholar
• Mitobe Y, Ikeda K, Suzuki T, et al. ESR1-stabilizing long noncoding RNA TMPO-AS1 promotes hormone-refractory breast cancer progression. Mol Cell Biol. 2019;39(23):e00261-19.
   Web of Science ®Google Scholar
• Basak P, Chatterjee S, Bhat V, et al. Long non-coding RNA H19 acts as an estrogen receptor modulator that is required for endocrine therapy resistance in ER+ breast cancer cells. Cell Physiol Biochem. 2018;51(4):1518–1532.
   PubMedGoogle Scholar
• Wu Q, Shi M, Meng W, et al. Long noncoding RNA FOXD3-AS1 promotes colon adenocarcinoma progression and functions as a competing endogenous RNA to regulate SIRT1 by sponging miR-135a-5p. J Cell Physiol. 2019;234(12):21889–21902.
   PubMed Web of Science ®Google Scholar
• Chen Y, Gao H, Li Y. Inhibition of LncRNA FOXD3-AS1 suppresses the aggressive biological behaviors of thyroid cancer via elevating miR-296-5p and inactivating TGF-beta1/Smads signaling pathway. Mol Cell Endocrinol. 2020;500:110634.
   PubMed Web of Science ®Google Scholar
• Guan Y, Bhandari A, Xia E, et al. lncRNA FOXD3-AS1 is associated with clinical progression and regulates cell migration and invasion in breast cancer. Cell Biochem Funct. 2019;37(4):239–244.
   PubMed Web of Science ®Google Scholar
• Salmena L, Poliseno L, Tay Y, et al. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011;146(3):353–358.
   PubMed Web of Science ®Google Scholar
• Dong Y, Xiao Y, Shi Q, et al. Dysregulated lncRNA-miRNA-mRNA network reveals patient survival-associated modules and RNA binding proteins in invasive breast carcinoma. Front Genet. 2019;10:1284.
   PubMed Web of Science ®Google Scholar
• Giannoudis A, Malki MI, Rudraraju B, et al. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer. Breast Cancer Res. 2020;22(1):126.
   PubMed Web of Science ®Google Scholar
• Ribas R, Pancholi S, Rani A, et al. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer. Breast Cancer Res. 2018;20(1):44.
   PubMedGoogle Scholar
• Ma JY, Liu SH, Chen J, et al. Metabolism-related long non-coding RNAs (lncRNAs) as potential biomarkers for predicting risk of recurrence in breast cancer patients. Bioengineered. 2021;12(1):3726–3736.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhou P, Li P, et al. Long non-coding RNA H19 regulates proliferation and doxorubicin resistance in MCF-7 cells by targeting PARP1. Bioengineered. 2020;11(1):536–546.
   PubMed Web of Science ®Google Scholar
• Ma T, Liang Y, Li Y, et al. LncRNA LINP1 confers tamoxifen resistance and negatively regulated by ER signaling in breast cancer. Cell Signal. 2020;68:109536.
   PubMed Web of Science ®Google Scholar
• Peng WX, Huang JG, Yang L, et al. Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer. Mol Cancer. 2017;16(1):161.
   PubMedGoogle Scholar
• Chen X, Gao J, Yu Y, et al. LncRNA FOXD3-AS1 promotes proliferation, invasion and migration of cutaneous malignant melanoma via regulating miR-325/MAP3K2. Biomed Pharmacother. 2019;120:109438.
   PubMed Web of Science ®Google Scholar
• Chen ZH, Hu HK, Zhang CR, et al. Down-regulation of long non-coding RNA FOXD3 antisense RNA 1 (FOXD3-AS1) inhibits cell proliferation, migration, and invasion in malignant glioma cells. Am J Transl Res. 2016;8:4106–4119.
   PubMed Web of Science ®Google Scholar
• Yang C, Zhang J, Ding M, Yang C, Zhang J, Ding M, et al. Ki67 targeted strategies for cancer therapy. Clin Transl Oncol. 2018;20(5):570–575.
   PubMed Web of Science ®Google Scholar
• Zeng Z, Zhao G, Zhu H, et al. LncRNA FOXD3-AS1 promoted chemo-resistance of NSCLC cells via directly acting on miR-127-3p/MDM2 axis. Cancer Cell Int. 2020;20(1):350.
   PubMed Web of Science ®Google Scholar
• Feng WT, Yao R, Xu LJ, et al. Effect of miR-363 on the proliferation, invasion and apoptosis of laryngeal cancer by targeting Mcl-1. Eur Rev Med Pharmacol Sci. 2018;22:4564–4572.
   PubMed Web of Science ®Google Scholar
• Song B, Yan J, Liu C, et al. Tumor Suppressor Role of miR-363-3p in Gastric Cancer. Med Sci Monit. 2015;21:4074–4080.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen T, Huang H, et al. miR-363-3p inhibits tumor growth by targeting PCNA in lung adenocarcinoma. Oncotarget. 2017;8(12):20133–20144.
   PubMedGoogle Scholar
• Tang J, Ma W, Zeng Q, et al. Identification of miRNA-based signature as a novel potential prognostic biomarker in patients with breast cancer. Dis Markers. 2019;2019:3815952.
   PubMed Web of Science ®Google Scholar
• Cao L, Wan Q, Li F, et al. MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition. BMB Rep. 2018;51(9):456–461.
   PubMed Web of Science ®Google Scholar
• Zhang R, Li Y, Dong X, et al. MiR-363 sensitizes cisplatin-induced apoptosis targeting in Mcl-1 in breast cancer. Med Oncol. 2014;31(12):347.
   PubMed Web of Science ®Google Scholar
• Li Y, Liu L, Lv Y, et al. Silencing long non-coding RNA HNF1A-AS1 inhibits growth and resistance to TAM of breast cancer cells via the microRNA-363/SERTAD3 axis. J Drug Target. 2021;29(7):724–753.
   Web of Science ®Google Scholar
• Irawan C, Atmakusumah D, Siregar NC, et al. Expression of biomarkers CXCR4, IL11-RA, TFF1, MLF1P in advanced breast cancer patients with bone metastatic: a diagnostic study. Acta Med Indones. 2016;48:261–268.
   PubMed Web of Science ®Google Scholar
• Ishibashi Y, Ohtsu H, Ikemura M, et al. Serum TFF1 and TFF3 but not TFF2 are higher in women with breast cancer than in women without breast cancer. Sci Rep. 2017;7(1):4846.
   PubMedGoogle Scholar
• Pelden S, Insawang T, Thuwajit C, et al. The trefoil factor 1 (TFF1) protein involved in doxorubicininduced apoptosis resistance is upregulated by estrogen in breast cancer cells. Oncol Rep. 2013;30(3):1518–1526.
   PubMed Web of Science ®Google Scholar
• Yang SX, Polley E, Lipkowitz S. New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. Cancer Treat Rev. 2016;45:87–96.
   PubMed Web of Science ®Google Scholar
• Araki K, Miyoshi Y. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. 2018;25(4):392–401.
   PubMed Web of Science ®Google Scholar
• Ribas R, Pancholi S, Guest SK, et al. AKT antagonist AZD5363 influences estrogen receptor function in endocrine-resistant breast cancer and synergizes with fulvestrant (ICI182780) In Vivo. Mol Cancer Ther. 2015;14(9):2035–2048.
   PubMed Web of Science ®Google Scholar